ICICI Direct: Intensifying Competition For Generic Revlimid - Cipla Impact
Cipla House, the headquarters of Cipla Ltd. in Lower Parel area of Mumbai, India. (Photo: BloombergQuint)

ICICI Direct: Intensifying Competition For Generic Revlimid - Cipla Impact

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Cipla Ltd. has announced the settlement of Revlimid (Lenalidomide) patent litigation with Celgene (Bristol Myers Squibb) in the U.S.

This makes Cipla the fourth player after Natco Pharma Ltd., Alvogen and Dr. Reddy’s Laboratories Ltd. to sign a settlement agreement with the innovator for gRevlimid.

Under the terms of the settlement, Celgene will provide Cipla with a license to sell generic volume-limited amounts of gRevlimid capsules in the U.S. sometime after March 2022 subject to regulatory approval.

This limited volume constraint will be applicable till January 2026.

Click on the attachment to read the full report:

ICICI Direct Pharma Sector Update Dec20.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.